Subsequent validation in our database confirmed these meta-analysis results, demonstrating that LINC-PINT downregulation is associated with tumor progression in specific cancers, such as prostate cancer, breast cancer, and lung cancer. The gene discussed is LINC-PINT; the disease is prostate carcinoma.